SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...
SAN DIEGO, June 15, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to ...
When dosing is optimized, biologics such as IFX are highly effective for managing CD and UC. Anser IFX testing uses a drug-tolerant homogeneous mobility shift assay (HMSA) to provide clinicians ...
The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...
SAN DIEGO, CA / ACCESSWIRE / May 9, 2024 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision medicine for immune-mediated diseases, announced the execution of provider agreements with ...
SAN DIEGO, March 28, 2017 /PRNewswire/ -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique ...
Prometheus Laboratories has been a leader in IBD patient care solutions for 30 years. Our continuum of tests empowers providers to diagnose, treat and help get IBD patients into remission faster with ...
Prometheus Laboratories' decision 10-plus years ago to patent a blood test that determines the maximum dose of a gastrointestinal drug is likely giving it major heartburn today. That's because the U.S ...
Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback